Leukopenia due to intra-arterial infusion chemotherapy for oral cancer

I : Clinical effects of recombinant human granulocyte colony-stimulating factor

Abstract

Recently we reported satisfactory clinical effects of the recombinant human granulocyte-colony stimulating factor (rhG-CSF) on neutropenia in cytotoxic chemotherapy for five cases of oral cancer histopathologically diagnosed as squamous cell carcinoma. Intra-arterial combination chemotherapies with TPP (THP-ADM, CDDP and PEP) for three cases and PP (CDDP and PEP) for two cases were carried out.
Subsequent recovery of the absolute neutrophil count was observed following repeated administrations of rhG-CSF (subcutaneous injection of therapy doses of 75μg/day for 3 days and maintaining doses of 25μg/day for 3 days) . The chemotherapy-induced neutropenic duration was shortened without side effects.
The administration of rhG-CSF is thus shown to reduce the hematopoietic toxicity of chemotherapy for oral cancer and indicate its possibility to enhance dose intensity.